NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Sunshine Biopharma Inc. SBFM
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$36.3M
▲ 4.1% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-25.7%
Net margin · FY25
-16.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 36.3M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 16 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-25.7%
Return on equity, FY2025
ROE
Operating margin-17.2%
Net margin-16.5%
Return on assets-19.7%
Each USD of equity lost 26 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -1.8M
Share of profit-0.0%
Consecutive raises—
Growth
+247.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+102.9%
+247.7%
+170.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 30.1M
total assets, end of FY2025
Total assetsUSD 30.1M
EquityUSD 23.0M
CashUSD 9.1M
Gross debtUSD 0.00
Net debtUSD -9.1M
Current ratio4.17×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
0.0
−0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
−7.32
−351.36
−1.76
−4.76
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−25.7
−23.0
−21.0
−244.9
·
·
·
·
·
·
·
·
−7945.3
−816.4
−371.8
−273.9
Shares out B
0.00
0.00
0.00
0.02
0.00
0.00
0.04
0.00
0.05
0.77
0.20
0.07
0.06
0.05
0.05
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed